Genes and cholestasis

Hepatology

Volumn 34, Issue 6, 2001, Pages 1067-1074

  Jansen, Peter L M ^a   Müller, Michael ^b   Sturm, Ekkehard ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CARRIER PROTEIN; CHENODEOXYCHOLIC ACID; CHOLIC ACID; URSODEOXYCHOLIC ACID;

ADAPTATION; CHOLESTASIS; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; GENE MUTATION; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; LIVER TRANSPLANTATION; MOLECULAR GENETICS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0035183471     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.29625     Document Type: Article

References (89)

1. Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter
2. Characterization of the transport properties of organic anion transporting polypeptide 1 (oatpl) and Na(+)/taurocholate cotransporting polypeptide (Ntcp): Comparative studies on the inhibitory effect of their possible substrates in hepatocytes and cDNA-transfected COS-7 cells
3. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6
4. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane
5. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver
6. Abnormal hepatic sinusoidal bile acid transport in an Amish kindred is not linked to FIC1 and is improved by ursodiol
7. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis
8. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors
9. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
10. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp
11. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis
12. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor
13. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism
14. Down-regulation of expression and function of the rat liver Na+/bile acid cotransporter in extrahepatic cholestasis
15. Sodium taurocholate cotransporting polypeptide is a serine, threonine phosphoprotein and is dephosphorylated by cyclic adenosine monophosphate
16. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases
17. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity
18. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids
19. Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver
20. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis
21. Expression of the bile salt export pump is maintained after chronic cholestasis in the rat
22. Characterization of inducible nature of MRP3 in rat liver
23. Cellular localization and upregulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver
24. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3)
25. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3)
26. Byler disease. Fatal familial intrahepatic cholestasis in an Amish kindred
27. Mapping of a locus for progressive familial intrahepatic cholestasis (Byler disease) to 18q21-q22, the benign recurrent intrahepatic cholestasis region
28. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): Evidence for heterogeneity
29. Sensorineural hearing loss associated with Byler disease
30. Histologic pathology of the liver in progressive familial intrahepatic cholestasis
31. Recurrent familial intrahepatic cholestasis in the Faeroe Islands. Phenotypic heterogeneity but genetic homogeneity
32. Fine-resolution mapping by haplotype evaluation: The examples of PFIC1 and BRIC
33. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis
34. Autosomal dominant benign recurrent intrahepatic cholestasis (BRIC) unlinked to 18q21 and 2q24
35. Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: A study of bile acid metabolism
36. Benign recurrent intrahepatic cholestasis. A report of 26 cases
37. Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase
38. Benign recurrent intrahepatic cholestasis: Improvement of pruritus and shortening of the symptomatic phase with rifampin therapy: A case report
39. Progressive familial intrahepatic cholestasis (PFIC): Evidence for genetic heterogeneity by exclusion of linkage to chromosome 18q21-q22
40. Locus heterogeneity in progressive familial intrahepatic cholestasis
41. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis
42. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis
43. Histologic pathology of the liver in progressive familial intrahepatic cholestasis
44. Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis
45. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis
46. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis
47. The wide spectrum of multidrug resistance 3 deficiency: From neonatal cholestasis to cirrhosis of adulthood
48. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease
49. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy
50. Progressive familial intrahepatic cholestasis
51. Selective surgical management of progressive familial intrahepatic cholestasis (Byler's disease)
52. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis
53. Progressive familial intrahepatic cholestasis: Partial biliary diversion normalizes serum lipids and improves growth in noncirrhotic patients
54. Orthotopic liver transplantation for Byler disease
55. Case report: Recurrence of progressive familial intrahepatic cholestasis (PFIC) in a living related liver transplant
56. Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy-and 3 beta,7 alpha, 12 alpha-trihydroxy-5-cholenoic acids
57. Identification of a new inborn error in bile acid synthesis: Mutation of the oxysterol 7 alpha-hydroxylase gene causes severe neonatal liver disease
58. Delta 4-3-oxosteroid 5 beta-reductase deficiency described in identical twins with neonatal hepatitis: A new inborn error in bile acid synthesis
59. Differential interaction of bile acids from patients with inborn errors of bile acid synthesis with hepatocellular bile acid transporters
60. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: Evidence for a defect in protein trafficking
61. Familial benign recurrent intrahepatic cholestasis. Interrelation with intrahepatic cholestasis of pregnancy and from oral contraceptives?
62. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: Effects on primary bile acids in babies and mothers
63. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy. A retrospective study of 19 cases
64. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: A randomized, double-blind study controlled with placebo
65. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis
66. Human bile salt export pump (BSEP) promoter is transactivated by the farnesoid X receptor/bile acid receptor (FXR/BAR)
67. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor
68. Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription
69. Progressive tubulointerstitial renal disease in infancy with associated hepatic abnormalities
70. Familial progressive tubulo-interstitial nephropathy and cholestatic liver disease - A newly recognized entity?
71. Progressive tubulointerstitial nephritis and chronic cholestatic liver disease
72. Familial occurrence of primary sclerosing cholangitis and ulcerative colitis
73. Sclerosing cholangitis in children
74. Sclerosing cholangitis of neoantal onset
75. Coincidental cases of primary sclerosing cholangitis and biliary atresia in siblings?
76. Familial clustering of infantile cirrhosis in Northern Germany: A clue to the etiology of idiopathic copper toxicosis
77. Endemic Tyrolean infantile cirrhosis: An ecogenetic disorder
78. Endemic Tyrolean infantile cirrhosis is not an allelic variant of Wilson's disease
79. Indian childhood cirrhosis (ICC): A complete classified review (1887-1980)
80. Serum gamma glutamyl transferase in Indian childhood cirrhosis
81. Increased hepatic copper concentration in Indian childhood cirrhosis
82. Cytoplasmic copper and its toxic effects. Studies in Indian childhood cirrhosis
83. Excess zinc associated with severe progressive cholestasis in Cree and Ojibwa-Cree children
84. Progressive familial intrahepatic cholestasis: A personal perspective
85. Severe familial cholestasis in North American Indian children: A clinical model of microfilament dysfunction?
86. Liver disease in Navajo neuropathy
87. Arthrogryposis, renal dysfunction and cholestasis syndrome: Report of five patients from three Italian families
88. Hereditary cholestasis with lymphoedema (Aagenaes syndrome, cholestasis-lymphoedema syndrome). New cases and follow-up from infancy to adult age
89. Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q